Stockscreener 앱 받기
1.205
1.26%
0.015
전일 마감가:
$1.19
열려 있는:
$1.16
하루 거래량:
14,896
Relative Volume:
0.01
시가총액:
$9.73M
수익:
$4.83M
순이익/손실:
$-2.99M
주가수익비율:
-2.5083
EPS:
-0.4804
순현금흐름:
$-2.83M
1주 성능:
-1.23%
1개월 성능:
+5.70%
6개월 성능:
+56.40%
1년 성능:
-37.56%
1일 변동 폭
$1.16
$1.205
1주일 범위
$1.16
$1.2995
52주 변동 폭
$0.6765
$2.39
이뮤론 Stock (IMRN) Company Profile
Compare IMRN vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMRN
Immuron Limited Adr
|
1.205 | 9.60M | 4.83M | -2.99M | -2.83M | -0.4804 |
VRTX
Vertex Pharmaceuticals Inc
|
521.78 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
789.70 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.85 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.98 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
202.84 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
이뮤론 주식(IMRN)의 최신 뉴스
With A$9M in cash and no borrowings, Immuron (NASDAQ: IMRN) narrowed its annual loss. - Stock Titan
Immuron Limited (IMRN) Presents at Coffee Microcaps Conference 2026Slideshow (NASDAQ:IMRN) 2026-09-22 - Seeking Alpha
IMRN - Finviz
symbol__ Stock Quote Price and Forecast - CNN
Immuron (NASDAQ: IMRN) Secures Exclusive U.S. Distribution Rights for PROIBS in $4.16 Billion Digestive Health Market - Kalkine Media
What Does Friday’s Move Mean for Immuron (NASDAQ:IMRN) on Nasdaq? - Kalkine Media
Stay updated with the stocks that are on the move in today's after-hours session. - ChartMill
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.51% - Investing.com
Immuron LimitedADR (IMRN) Peer Comparison – Compare with Others - Value Research
Gold Falls Over 1%; American Outdoor Brands Shares Jump After Q1 Results - Benzinga
Dow Falls Over 100 Points; US Economy Adds 162,000 Jobs In August - Benzinga
IMRN Stock Jumps As Immuron Beats Guidance And Advances Pipeline - StocksToTrade
IMRN Stock Pops As Immuron Beats Guidance And Advances Pipeline - StocksToTrade
$4.16B US gut health market in sight for Immuron (IMRN) with new PROIBS distribution deal - Stock Titan
Immuron (ASX:IMC; NASDAQ:IMRN) Brings European-Certified Medical Device PROIBS® To U.S. Consumers - kalkinemedia.com
Immuron Limited WarrantsADR (IMRNW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Immuron (NASDAQ: IMRN) ends FY26 with A$9.0m cash but stays in loss - Stock Titan
Immuron Reports FY26 Preliminary Results - Barchart.com
Kazia Therapeutics LimitedADR Peer Comparison – Compare with Others - Value Research
Immuron (IMRN) lifts FY26 sales as it shifts to partner-funded drug development - Stock Titan
Immuron (ASX: IMC) Pushes IMM-529 Forward with FDA Clearance and Partnering Strategy - Kalkine Media
Immuron Limited (NASDAQ: IMRN) highlights antibody platform and CEO talk at Emerging Growth Conference - Stock Titan
Immuron (IMRN) Holds Gains Above $1.10 as Micro-Cap Biotech Finds Buying InterestCash Secured Put - dars.gov.et
PRU Q2 2026 Earnings: EPS Beats Estimates by 14.5% as Prudential Delivers Strong ResultsRevenue Breakdown Analysis - vinanet.vn
GLIBK Q1 2026 Earnings: EPS Misses Estimates by 63.89%, Coming in at $0.45 per ShareTangible Book Value - vinanet.vn
Immuron Limited (IMRN) Slips 1.8% as ADR Tests Key $1.04 SupportMutual Fund Flow - vinanet.vn
Immuron (NASDAQ: IMRN) outlines FY26 growth, cash runway and CDI IND plans - Stock Titan
Immuron Limited Sponsored ADR Revenue Breakdown – MUN:ANWA - TradingView
Immuron Limited Sponsored ADR Revenue Breakdown – LSX:A2DTD8 - TradingView
Immuron Limited (NASDAQ: IMRN) highlights antibody platform at TechKnow Invest - Stock Titan
Immuron Limited (NASDAQ: IMRN) grows FY26 revenue to A$7.7m - Stock Titan
Immuron CEO, Steven Lydeamore presentation at Kalkine Media Webinar - Barchart.com
Immuron FY26 SalesFour Consecutive Quarters of Growth over Prior Year - Sahm
BNY Mellon Lifts Substantial Holding in Immuron to 44.61% via ADR Program Deposits - Kalkine
Immuron (NASDAQ: IMRN) lifts FY26 Travelan sales 6% to AUD$7.7m - Stock Titan
BNY Mellon Boosts Immuron Stake to 44.61% Through ADR Share Deposits by July 2026 - Kalkine Media
AVANTEL.NS Mar 2026 Earnings: EPS of ₹0.27 on Revenue of ₹63.15 CroreOne-Time Loss Impact - vinanet.vn
Immuron (NASDAQ: IMRN) advances IMM-529 CDI drug with new partnering push - Stock Titan
Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy - GlobeNewswire Inc.
Immuron (ASX:IMC) Pursues Strategic Partnership to Advance FDA IND-Cleared IMM-529 - Kalkine Media
A2DTD8 Forecast — Price Target — Prediction for 2027 - TradingView
ANWA Forecast — Price Target — Prediction for 2027 - TradingView
Immuron (NASDAQ: IMRN) now has 322.8M ordinary shares on issue - Stock Titan
Price to earnings forward of Immuron Limited Sponsored ADR – MUN:ANWA - TradingView
Immuron Limited Sponsored ADR Actuals & Estimates (NASDAQ:IMRN) - TradingView
Form 6K Immuron Ltd ADR For: 23 June By Investing.com - Investing.com South Africa
Form 6K Immuron Ltd ADR For: 23 June - Investing.com UK
Immuron (NASDAQ: IMRN) cancels 3.8M shares in small holder buy-back - Stock Titan
Immuron (NASDAQ: IMRN) reports expiry of 1.43M options and updated capital - Stock Titan
63MOONS.NS Q2 2026 Earnings: Revenue Surge of 351% YoY but Net Loss PersistsTrough Earnings Signal - Vinanet
ADVAIT.NS Mar 2026 Earnings: Robust Profitability Amidst Expanding OperationsEarnings Beat Streak - vinanet.vn
이뮤론 (IMRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.00%
1.10%
자본화:
|
볼륨(24시간):